Wuxi Biologics Unspadr2 Stock Fundamentals
| 1FW1 Stock | EUR 3.38 0.14 3.98% |
WUXI BIOLOGICS UNSPADR2 fundamentals help investors to digest information that contributes to WUXI BIOLOGICS's financial success or failures. It also enables traders to predict the movement of WUXI Stock. The fundamental analysis module provides a way to measure WUXI BIOLOGICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to WUXI BIOLOGICS stock.
WUXI |
WUXI BIOLOGICS UNSPADR2 Company Shares Outstanding Analysis
WUXI BIOLOGICS's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current WUXI BIOLOGICS Shares Outstanding | 2.11 B |
Most of WUXI BIOLOGICS's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, WUXI BIOLOGICS UNSPADR2 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, WUXI BIOLOGICS UNSPADR2 has 2.11 B of shares currently outstending. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The shares outstanding for all Germany stocks is significantly lower than that of the firm.
WUXI BIOLOGICS UNSPADR2 Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining WUXI BIOLOGICS's current stock value. Our valuation model uses many indicators to compare WUXI BIOLOGICS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across WUXI BIOLOGICS competition to find correlations between indicators driving WUXI BIOLOGICS's intrinsic value. More Info.WUXI BIOLOGICS UNSPADR2 is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers reporting about 0.45 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for WUXI BIOLOGICS UNSPADR2 is roughly 2.23 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the WUXI BIOLOGICS's earnings, one of the primary drivers of an investment's value.WUXI Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses WUXI BIOLOGICS's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of WUXI BIOLOGICS could also be used in its relative valuation, which is a method of valuing WUXI BIOLOGICS by comparing valuation metrics of similar companies.WUXI BIOLOGICS is currently under evaluation in shares outstanding category among its peers.
WUXI Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.31 % | |||
| Shares Outstanding | 2.11 B | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | 238.12 X | |||
| Revenue | 13.09 B | |||
| Gross Profit | 4.83 B | |||
| EBITDA | 4.6 B | |||
| Net Income | 1.69 B | |||
| Cash And Equivalents | 8.48 B | |||
| Cash Per Share | 4.15 X | |||
| Total Debt | 3.33 B | |||
| Debt To Equity | 0.16 % | |||
| Current Ratio | 3.16 X | |||
| Book Value Per Share | 16.51 X | |||
| Cash Flow From Operations | 1.88 B | |||
| Earnings Per Share | 0.25 X | |||
| Number Of Employees | 10.59 K | |||
| Beta | 1.11 | |||
| Market Capitalization | 32.39 B | |||
| Z Score | 5.4 |
About WUXI BIOLOGICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze WUXI BIOLOGICS UNSPADR2's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of WUXI BIOLOGICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of WUXI BIOLOGICS UNSPADR2 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.WuXi Biologics Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the Peoples Republic of China, North America, Europe, and internationally. WuXi Biologics Inc. is a subsidiary of WuXi Biologics Holdings Limited. WUXI BIOLOGICS is traded on Frankfurt Stock Exchange in Germany.
Currently Active Assets on Macroaxis
Other Information on Investing in WUXI Stock
WUXI BIOLOGICS financial ratios help investors to determine whether WUXI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in WUXI with respect to the benefits of owning WUXI BIOLOGICS security.